On this page we presented the HALO Historical PE Ratio information for Halozyme Therapeutics' stock. The average HALO historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 64.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average HALO historical PE based on this TTM earnings result method is 35.8. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this HALO historical PE result, against the recent PE: when this page was posted on 3/11/2024, the most recent closing price for HALO had been 41.20, and the most recent quarterly earnings result, annualized, was 3.28. Meanwhile, the most recent TTM earnings summed to 2.78. From these numbers, we calculate the recent HALO PE on 3/11/2024 based on annualized quarterly EPS was 12.6. Based on HALO's history, that recent PE is low relative to the historical average, with the recent PE 80.3% lower than the historical average PE across our data set for Halozyme Therapeutics. Looking at the recent HALO PE on 3/11/2024 based on TTM EPS, we calculate the ratio at 14.8. Based on HALO's history, that recent PE is low relative to the historical average, with the recent PE 58.7% lower than the average PE across our Halozyme Therapeutics data set with TTM EPS used in the calculation at each period.

Another interesting HALO historical PE Ratio calculation we look at is to take the median earnings per share of the last four quarters for HALO, and then annualize the resulting value... with that annualized number then being used in the PE calculation. To walk through this math for HALO, we start with the past four EPS numbers and we first sort them from lowest to highest: 0.47, 0.74, 0.75, and 0.82. We then toss out the highest and lowest result, and then take the average of those two middle numbers — 0.74 and 0.75 — which gives us the median of 0.74. Basically the way to think about this 0.74 number is this: for the trailing four earnings reports, 0.74 marks the "middle ground" number where HALO has reported a value higher than 0.74 half the time, and has reported a value lower than 0.74 half the time. Annualizing that median value then gets us to 2.96/share, which we use as the denominator in our next PE calculation. With 41.20 as the numerator (as of 3/11/2024), the calculation is then 41.20 / 2.96 = 13.9 as the HALO PE ratio as of 3/11/2024, based on that annualized median value we calculated.

For self directed investors doing their due diligence on HALO or any other given stock, valuation analysis for HALO can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Halozyme Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for HALO. Thanks for visiting, and the next time you need to research HALO Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.